Machine-learning risk stratification for 12-month mortality and SGLT2 inhibitor-related absolute risk differences in elderly patients with heart failure and type 2 diabetes
The Journal of Cardiovascular Aging · 02.11.2026 · 6 (4)
DOI: 10.20517/jca.2026.111 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Cardiovascular Aging, online erschienen am 02.11.2026. Verfasst von Zhen Qin und 11 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Aim
Older adults with heart failure (HF) and type 2 diabetes mellitus (T2DM) face high 12-month mortality. We developed a routine-variable model for mortality prediction and explored SGLT2 inhibitor (SGLT2i)-related absolute risk differences across model-defined risk strata.
Methods
This retrospective study included 500 hospitalized patients aged ≥ 75 years with HF and T2DM. Three feature sets (guideline-informed core, primary analysis, and complete imputed candidate) and ten algorithms were compared using repeated five-fold outer/four-fold inner cross-validation with training-fold preprocessing. Cox and multiple-imputation sensitivity analyses were performed. SGLT2i associations were assessed using propensity-score overlap weighting.
Results
The binary modelling cohort included 434 patients with 167 deaths (38.5%). The nested selection workflow achieved a mean area under the receiver operating characteristic curve (AUROC) of 0.729, area under the precision-recall curve of 0.612, and Brier score of 0.206. Cox sensitivity analysis yielded a censoring-adjusted 365-day AUROC of 0.755; multiple imputation gave an AUROC of 0.758 for the fixed gradient-boosting reference. Among 381 patients, weighted 12-month mortality was 16.1% in SGLT2i users vs. 31.1% in non-users, a difference of 15.0 percentage points (95%CI: 5.9-23.9). Stratum-specific differences were 6.5, 18.1, and 19.7 percentage points, with wide confidence intervals. A six-variable interactive interface supported risk communication.
Conclusion
Routine clinical variables supported moderately discriminative mortality risk stratification under nested validation. SGLT2i use was associated with lower adjusted 12-month mortality overall; larger studies are needed to establish whether associations differ across risk strata. External and prospective validation remains necessary.
Zitieren
APA
Qin, Z., Jin, Y., Li, X., Lan, B., Wu, K., Zou, J., Liu, T., Wang, Y., Zhang, N., Zhang, J., Yuan, J., & Tang, J. (2026). Machine-learning risk stratification for 12-month mortality and SGLT2 inhibitor-related absolute risk differences in elderly patients with heart failure and type 2 diabetes. The Journal of Cardiovascular Aging, 6(4). https://doi.org/10.20517/jca.2026.111
Vancouver
Qin Z, Jin Y, Li X, Lan B, Wu K, Zou J, et al. Machine-learning risk stratification for 12-month mortality and SGLT2 inhibitor-related absolute risk differences in elderly patients with heart failure and type 2 diabetes. The Journal of Cardiovascular Aging. 2026;6(4). doi:10.20517/jca.2026.111
BibTeX
@article{Qin2026,
author = {Qin, Zhen and Jin, Yitong and Li, Xiang and Lan, Bo and Wu, Kaiwen and Zou, Jieru and Liu, Tiansheng and Wang, Yongshun and Zhang, Naijin and Zhang, Jinying and Yuan, Jie and Tang, Junnan},
title = {Machine-learning risk stratification for 12-month mortality and SGLT2 inhibitor-related absolute risk differences in elderly patients with heart failure and type 2 diabetes},
journal = {The Journal of Cardiovascular Aging},
year = {2026},
volume = {6},
number = {4},
doi = {10.20517/jca.2026.111}
}
EUVIMED